Triptorelin acetate administration in early pregnancy: case reports and review of the literature

Chardonnens, Didier; Sylvan, Kirsten; Walker, Dilys; Bischof, P.; Sakkas, Denny; Campana, A.

doi:10.1016/s0301-2115(98)00109-2

Cited by 13 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Les agonistes de la GnRH ont é té initialement considé ré s dé lé tè res pour l'implantation [15]. La mé ta-analyse de Chardonnens é tudiant l'administration inopiné e d'agonistes chez des femmes enceintes ne retrouvait pas d'effet luté olytique [16].…”

Section: Discussionunclassified

Administration d’agonistes de la GnRH (Gonadotrophin Releasing Hormone) en phase lutéale des protocoles substitutifs de transferts d’embryons congelés : étude prospective randomisée

Gogce

Benchaïb

Hadj

et al. 2015

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

Section: Discussionunclassified

Administration d’agonistes de la GnRH (Gonadotrophin Releasing Hormone) en phase lutéale des protocoles substitutifs de transferts d’embryons congelés : étude prospective randomisée

Gogce

Benchaïb

Hadj

et al. 2015

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

“…In premenopausal patients, aromatase inhibitors should be always associated with GnRHa. Use of ovarian suppression causes a condition of iatrogenic transitory menopause that is unlikely to be associated with a spontaneous pregnancy; nevertheless, some cases of pregnancy occurring during administration of GnRHa have been described 35 . Therefore, GnRHa use should not be considered a contraception method 36 .…”

Section: Pregnancy After Breast Cancermentioning

confidence: 99%

“…Use of ovarian suppression causes a condition of iatrogenic transitory menopause that is unlikely to be associated with a spontaneous pregnancy; nevertheless, some cases of pregnancy occurring during administration of GnRHa have been described. 35 Therefore, GnRHa use should not be considered a contraception method. 36 When GnRHa is suspended, ovarian activity is expected to resume in most patients.…”

mentioning

confidence: 99%

Update on Pregnancy Following Breast Cancer Diagnosis and Treatment

et al. 2022

View full text Add to dashboard Cite

Survivorship has become a crucial component in breast cancer care. For women who have not completed their family planning, conceiving at the end of anticancer treatments should not be discouraged but might be challenging. Oncofertility counseling should be offered at the time of diagnosis to all patients, in order to inform them about the potential treatment-induced gonadotoxicity as well as the available strategies for fertility preservation, thus allowing to increase the chances of a future pregnancy. This article reports an updated overview on the current state of the art on pregnancy in women with prior breast cancer diagnosis and treatment, with a main focus on the issues faced by patients with history of hormone receptor–positive disease and BRCA carriers.

show abstract

“…During the late 20th century, several case reports suggested that accidental administration of GnRHagonist (GnRH-a) is not only safe towards IVF pregnancies, but also might play a role in successful implantation [4][5][6][7][8][9][10][11][12][13][14]. Moreover, a prospective controlled study by Tesarik et al supported those observations [15].…”

Section: Introductionmentioning

confidence: 99%

Comparison of pregnancy rates in antagonist cycles after luteal support with GnRH-agonist versus progesterone – prospective randomized study

Buhbut

Nabulsi²,

Avigdor³

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: To compare pregnancy rates in GnRH-antagonist cycles triggered with hCG after luteal phase support with intranasal GnRH agonist as sole luteal phase support versus standard vaginal progesterone preparation. Methods: Prospective randomized controlled study of patients who underwent antagonist-based IVF cycles triggered with hCG at university-affiliated tertiary medical center between 2020 and 2022. Patients meeting the inclusion criteria were randomly assigned to either intranasal GnRH-agonist or vaginal progesterone for luteal phase support. Pregnancy rates were the main outcome compared between the two study groups. Results: A total of 150 patients underwent 164 cycles, 127 cycles of which were included in the study cohort. Of them, 64 (50.4%) and 63 (49.6%) cycles were treated with GnRH-agonist or progesterone respectively as sole luteal phase support. A significantly higher pregnancy rate was demonstrated in the GnRH-agonist group compared with the progesterone group. After adjustment of several potential confounders such as age, body mass index, past obstetric history, number of IVF cycles, oocyte retrieved and embryos transferred, GnRH-agonist was still associated with a higher pregnancy rate (odds ratio 3.4, 95% confidence interval 1.4-8.3). Ovarian hyperstimulation syndrome rates were similar between the groups. Conclusions: This prospective study suggests that nasal GnRH-agonist for luteal phase support is associated with higher pregnancy rates compared with standard progesterone support in an antagonist-based protocol triggered with hCG, while maintaining a similar safety profile.

show abstract

Triptorelin acetate administration in early pregnancy: case reports and review of the literature

Cited by 13 publications

References 62 publications

Administration d’agonistes de la GnRH (Gonadotrophin Releasing Hormone) en phase lutéale des protocoles substitutifs de transferts d’embryons congelés : étude prospective randomisée

Administration d’agonistes de la GnRH (Gonadotrophin Releasing Hormone) en phase lutéale des protocoles substitutifs de transferts d’embryons congelés : étude prospective randomisée

Update on Pregnancy Following Breast Cancer Diagnosis and Treatment

Comparison of pregnancy rates in antagonist cycles after luteal support with GnRH-agonist versus progesterone – prospective randomized study

Contact Info

Product

Resources

About